DV
Dividend Vision

HIMS Stock — Hims & Hers Health Inc.

Hims & Hers Health Inc. (HIMS)

Updated November 17, 2026.

HIMS is a stock. Total return is 79.1% over the past 7.2 years, 91.0 points behind SPY at 170.1%.

Hims & Hers Health operates a consumer-focused digital health platform that connects patients with licensed healthcare professionals across multiple countries, offering prescription medications, over-the-counter products, cosmetics, supplements, and laboratory testing services through its websites and mobile application. The company does not currently distribute to shareholders. The platform specializes in areas including general wellness, skincare, sexual health, hair care, hormone health, weight loss, dermatology, and mental health, with products available through direct online channels and retail partnerships.

HIMS performance versus SPY

Total return is 79.1% over the past 7.2 years, 91.0 points behind SPY at 170.1%. Over the past year its total return — price change plus distributions reinvested — is -50.7%. Its deepest 1-year drawdown was 63.7%.

WindowTotal returnCAGR
1M-37.5%—
3M-38.7%—
6M-29.9%—
YTD-45.9%—
1Y-50.7%—
2Y CAGR—-4.70%
3Y CAGR—32.90%
5Y CAGR—16.70%
Since inception 2019-09-13 · 7.2 years79.1%8.50%

HIMS key facts

Asset type
Stock
Asset class
Equity
Inception date
09/13/2019
Distribution frequency
None
Last close
$17.55 (as of 2026-11-17)
Market cap
$3,966,910,722
Average volume
13,114,000
Beta
2.502
Payout ratio
0.0%
Forward P/E
51.28
EPS
-$0.83

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HIMS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 63.7%.

Who may consider HIMS — and who may not

It is a weaker fit for investors who need monthly cash flow (HIMS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HIMS

Tagged: Healthcare, Pharmaceutical.

Compare HIMS

HIMS vs similar funds:

Frequently asked questions

Does HIMS pay monthly?

No. HIMS does not currently distribute.

When does HIMS pay a dividend?

HIMS does not currently distribute.

How has HIMS performed?

Total return is 79.1% over the past 7.2 years, 91.0 points behind SPY at 170.1%. Over the past year its total return — price change plus distributions reinvested — is -50.7%. Its deepest 1-year drawdown was 63.7%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.